The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of nirogacestat in patients with desmoid tumor and adenomatous polyposis coli (APC) mutation: Phase 3 DeFi analyses.
 
Bernd Kasper
Honoraria - Bayer; GlaxoSmithKline; Pharmamar-zeltia
Consulting or Advisory Role - Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; GlaxoSmithKline; SpringWorks Therapeutics
Research Funding - Ayala Pharmaceuticals (Inst); Cogent Medicine (Inst); PharmaMar (Inst); SpringWorks Therapeutics (Inst)
 
Noah Federman
Stock and Other Ownership Interests - Moderna Therapeutics
Consulting or Advisory Role - Bayer; SpringWorks Therapeutics
Speakers' Bureau - Bayer; Fennec Pharma; Springworks Therapeutics
Research Funding - Mirati Therapeutics
 
Peter Reichardt
Honoraria - Boehringer Ingelheim (Inst); Clinigen Group (Inst); Deciphera (Inst); PharmaMar (Inst)
Consulting or Advisory Role - Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Mundipharma (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst)
Research Funding - Novartis (Inst)
 
Steven Attia
Research Funding - Adaptimmune (Inst); Advenchen Laboratories (Inst); Ayala Pharmaceuticals (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); BTG (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Guardant Health; Incyte (Inst); InhibRx (Inst); Jazz Pharmaceuticals (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Monopar Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); Salarius Pharmaceuticals (Inst); Shanghai Pharma (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst)
 
Allison Lim
Employment - SpringWorks Therapeutics
Stock and Other Ownership Interests - SpringWorks Therapeutics
 
Vincent Amoruccio
Employment - SpringWorks Therapeutics
 
Sunny Cho
Employment - SpringWorks Therapeutics
Stock and Other Ownership Interests - SpringWorks Therapeutics
 
Richard F. Riedel
Employment - Limbguard (I)
Leadership - Limbguard (I)
Stock and Other Ownership Interests - Limbguard (I)
Consulting or Advisory Role - AADi; Adaptimmune; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; GlaxoSmithKline; NanoCarrier; SpringWorks Therapeutics
Research Funding - AADi (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); NanoCarrier (Inst); Oncternal Therapeutics (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I)
Travel, Accommodations, Expenses - Daiichi Sankyo; Deciphera; NanoCarrier; SpringWorks Therapeutics